CITI VIEW ON PHARMA
Continue To Assign Low Probability To Scenario Of US Imposing Tariffs On Indian Pharma Cos
Analysing Worst Case Scenario Of 10% Tariff
Cos With High Exposure Like Zydus, Dr Reddy, Aurobindo Could Take 9-12% EBITDA Hit
EBITDA Hit Would Reduce To 5-6% If Part Of Tariffs Is Passed On To Buyers; Full Pass-Through Is Tough
Cos With Low Exposure Like Torrent Pharma, Sun Pharma, Divi's Labs Could Take A Hit Of 1-3%
Continue To Assign Low Probability To Scenario Of US Imposing Tariffs On Indian Pharma Cos
Analysing Worst Case Scenario Of 10% Tariff
Cos With High Exposure Like Zydus, Dr Reddy, Aurobindo Could Take 9-12% EBITDA Hit
EBITDA Hit Would Reduce To 5-6% If Part Of Tariffs Is Passed On To Buyers; Full Pass-Through Is Tough
Cos With Low Exposure Like Torrent Pharma, Sun Pharma, Divi's Labs Could Take A Hit Of 1-3%
